Orphazyme A/S ORPH
Day range unavailable
52-week range unavailable
- Market cap
- 37.27M
- Revenue (ttm)
- 13.15M
- Shares out
- 35.31M
- Forward P/E
- -0.53
- Beta
- 0.80
- Analysts
- Sell
- Price target
- 1.00 (+14.9%)
2Y -3.1500 (-78.36%)
Key statistics
- Enterprise value
- -250.04M
- PEG ratio
- 0.00
- Price / sales
- 2.83
- Price / book
- 0.18
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -392.38M
- Total cash
- 334.18M
- Total debt
- 58.59M
- Return on equity
- -251.34%
- Short % of float
- 0.00%
- 50-day average
- 1.39
- 200-day average
- 3.45
Analyst view
Consensus: sell
- Strong buy0
- Buy0
- Hold0
- Sell0
- Strong sell1
Next earnings
Consensus EPS estimate 0.00.
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 30, 2021 | B of A Securities | down | Neutral | Underperform |
About Orphazyme A/S
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Denmark
- Website
- orphazyme.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on ORPH — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Renaissance Technologies, LLC | 0.77% | 271,994 | 655.50K | Dec 30, 2021 |
| Geode Capital Management, LLC | 0.50% | 177,074 | 426.75K | Dec 30, 2021 |
| Two Sigma Investments, LP | 0.40% | 141,117 | 340.09K | Dec 30, 2021 |
| Profund Advisors LLC | 0.36% | 127,524 | 307.33K | Dec 30, 2021 |
| Susquehanna International Group, LLP | 0.32% | 114,372 | 275.64K | Dec 30, 2021 |
| Optiver Holding B.v. | 0.30% | 106,836 | 257.47K | Dec 30, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index ETF | 0.44% | 154,926 | 306.75K | Jan 30, 2022 |
| ProFunds-VP Europe 30 | 0.31% | 109,548 | 264.01K | Dec 30, 2021 |
| Fidelity NASDAQ Composite Index Fund | 0.06% | 21,566 | 51.97K | Dec 30, 2021 |